Agent-in-Place - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Agent-in-Place

Mice on a Mission

December 2, 2012

Pharmaceutical Technology

To ensure the accuracy of scientific testing, protect the subjects to avoid data contamination.

Frozen Assets

November 2, 2012

Pharmaceutical Technology

Even when all is well at the facility, one must expect the worst while braving the elements.

Case Closed

October 2, 2012

Pharmaceutical Technology

Only the strong survive when it comes to pharmaceutical packaging and shipping.

Compliant or Contraband?

September 2, 2012

Pharmaceutical Technology

International trade can be great for business, but breaking border laws can put one in hot water.

Technology Fights Back

August 2, 2012

Pharmaceutical Technology

Meticulous system configuration can prevent machines from taking over.

A Lukewarm Reception

July 2, 2012

Pharmaceutical Technology

Careful attention to detail will help to prevent valuable assets from "melting" away.

A "Big E" on the Scoreboard

June 2, 2012

Pharmaceutical Technology

Even the slightest of errors in exponential calculations can cause the biggest of headaches.

All Eyes Alert

May 2, 2012

Pharmaceutical Technology

It's better to catch costly mistakes in the laboratory before they reach the accounting department.

Loose Lips Sink Ships

April 2, 2012

Pharmaceutical Technology

Failure to disclose info may work sometimes, but eventually every question will be answered.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here